PubMed Health⌕ Search

Biomedical subjects

J Vardi

Publications and source records attributed to J Vardi.

16 recordsLinked to original sources
PubMed1979

Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading.

Dopamine-Beta-Hydroxylase (D.B.H.)-activity was measured in the plasma of untreated Parkinsonian patients, after tretment with L-dopa and 2-Bromo-alpha-ergocriptine. The findings were compared to the D.B.H.-activity of a matched healthy control group. After L-dopa loading D.B.H.-activity decreased in the Parkinsonian patients by 27.6 +/- 3.1% compared to 16.2 +/- 3.3% (p less than 0.02) in the control group. After 2-Bromo-alpha-ergocriptine laoding the decrease in D.B.H.-activity was 32.6 +/- 4.4% in the parkinsonian patients, and 158 +/- 4.9% (p less than 0.02) in the control group. This reduced D.H.B.-activity after L-dopa loading may reflect an impairment, in the Parkinsonian patients' ability to metaoblize L-dopa. The reduced D.B.H.-activity after treatment with 2-Bromo-alpha-ergocriptine may be explained by a pronounced antagonistic influence of 2-Bromo-alpha-ergocriptine on the presynaptic dopamine receptors, suggesting that presynaptic dopaminergic receptors are involved in Parkinson's disease.

Bromocriptine↗
PubMed1979

EEG sleep patterns in Parkinsonian patients treated with bromocryptine and L-dopa: a comparative study.

The nocturnal sleep patterns of six Parkinsonian patients treated with Bromocryptine (2-Br-L-ergocryptine CB-154), a dopamine-like agonist, were compared with those of the same patients under L-DOPA treatment. No significant differences were found between the two groups. It is suggested that Bromocryptine, acting on dopamine receptors in the sleep regulating systems at the reticular level in the midbrain has the same effect on sleep patterns of Parkinsonian patients as L-DOPA.

Aged↗
PubMed1978

Myoclonic attacks induced by L-dopa and bromocryptin in Parkinson patients: a sleep EEG study.

Six patients with Parkinson's disease developed nocturnal myoclonic attacks after prolongued treatment with L-Dopa which were electroencephalographically recorded. These symptoms persisted after treatment with 2 bromo-alpha-ergocryptin (Bromocryptin), a dopamine receptor agonist, which was substituted for L-Dopa. Bromocryptin is known to have no pre- or postsynaptic effect on serotonin metabolism. It is proposed that these myoclonic phenomena are the expression of the hypersensitivity of denervated catecholamine receptors in the brainstem to the stimulation of L-Dopa and Bromocryptin. This thesis differs with previous suggestions that serotonin plays a major role in the genesis of myoclonic seizures in Parkinsonian patients treated with L-Dopa.

Aged↗
PubMed1978

Kleine-Levin syndrome with periodic apnea during hypersomnic stages--E.E.G. study.

A 33 year old male, suffering from Kleine-Levine syndrome associated with periods of apnea during the hypersomnic attacks, is reported. Ventilatory studies negate the Pickwickian syndrome. The E.E.G.'s recorded during the hypersomnic attacks and the apneic periods showed a direct correlation between high-voltage delta waves paroxysmal E.E.G. activity, and apneic period. Medications known to improve Kleine-Levin syndrome, in our case, had no effect upon the clinical hypersomnic and apnea periods, nor on the correlatives E.E.G.'s pattern and spirometric studies. Theoretical considerations let us assume that these paroxysmal E.E.G. patterns associated with apnea are NRem-sleep serotonin dependent, and have an inhibitory influence on the respiratory centers, by alternating the equilibrium between the catecholamines and acetylcholine activities.

Adult↗
PubMed1978

EEG sleep study in parkinsonian patients under bromocryptine treatment.

Nocturnal sleep patterns were registered from 6 parkinsonian patients treated with bromocryptine, ("-Br-L-ergocryptine, C.B.-154) a dopamine-like agonist. No significant differences in their sleep patterns were found in comparison with patients treated with L-dopa. Since bromocryptine acts direct on the dopaminergic receptor sites, it is suggested that the disturbed EEG sleep patterns in parkinsonian patients cannot be explained by altered dopaminergic or serotoninergic effects whether pre- or postsynaptic.

Aged↗
PubMed1977

Measurement of prostaglandin E2 in cerebrospinal fluid in patients suffering from stroke.

In 16 patients suffering from cerebrovascular events, prostaglandin (PG) E2 was measured in their cerebrospinal fluid and correlated with their clinical status and evolution. Prostaglandin E2 ranged from 200-3000 pg (picogram)/ml of cerebrospinal fluid. A positive correlation was found between PG E2 levels and the severity and clinical outcome of the stroke.

Adult↗
PubMed1976

Toxemia of pregnancy. Part II. Immunofluorescent studies with placental connective tissue antisera: the possibility of characteristic lesions.

Seventeen placentas from term gestation complicated by toxemia of pregnancy and 17 normal controls were tested by the fluorescent antibody technic. Antisera to normal placental connective tissue and toxemic placental connective tissue were used. The antisera were obtained by the injection into rabbits of placental extracts rich in connective tissue elements from normal and toxemic placentas. The antitoxemic antisera, after absorption with soluble sonic fraction of normal placentas, stained the following elements exclusively in 14 of the 17 placentas: part of the syncytial knots, fibrillar elements in the adventitia of blood vessels, and amorphous deposition of connective tissue. In each of the remaining three placentas at least two of the lesions were observed. The observation of bright fluorescence in part of the syncytiotrophoblasts and the syncytial knots in toxemic placentas led to the suggestion that they arise late in pregnancy during the disease. The thin fibrillar elements and the amorphous deposition of connective tissue were documented in the various developmental stages in toxemic and normal placentas as well. These findings established possible characteristic lesions in the placenta of pregnancies complicated by toxemia.

Adolescent↗
PubMedDate not supplied

R.H.I.S.A. -- cysternography study in sporadic choreo-athetotic syndrome accompanied with dementia (sporadic Huntington disease).

Seven patients who suffered from choreo-athetotic movements, accompanied by slowly progressive mental and affective decline over several years, without hereditary background, were admitted for clinical and psychodiagnostic tests. Laboratory examinations and anamnestic data were negative, and therefore a presumed diagnosis of sporadic Huntington disease was made. In order to verify the diagnosis, we had done P.E.G. -- Contrast study, and R.H.I.S.A. -- Cysternography. The P.E.G. -- Contrast demonstrated an enlargement of the sub-arachnoidal space and a symmetrical enlargement of the ventricular System, that may represent cortical and sub-cortical atrophy. The R.H.I.S.A. -- Cysternography Study showed in our patients the characteristics of the Mixed type Pattern: combined ventricular penetration with delayed para-sagittal absorption. Considering the results of the R.H.I.S.A. Studies, that correspond to the P.E.G. -- Contrast Studies, and its invulnerability towards patients, we presume that R.H.I.S.A. may be preferred as a diagnostic tool in Sporadic Huntington Disease.

Aged↗
PubMedDate not supplied

[Effect of bromocriptine on secretion of the enzyme dopamine-B-hydroxylase (DBH) in patients with Parkinson's disease].

The activity of DBH enzyme was measured in plasma of 7 non treated patients suffering from Parkinson's disease; a 10 mg dose of Bromocryptine was administered per os to these patients. Attained results were compared to the enzyme activity in a group of control of 7 healthy individuals. It was pointed out that in patients suffering from Parkinson's disease the decrease of DBH level in plasma after the administration of Bromocryptine was of 32.6% +/- SE 4.4% while in the group of control the decrease was only of 15% +/- SE 4.9%. This decrease in the plasmatic level of the enzyme after the administration of Bromocryptine should be due to the marked antagonistic activity of Bromocryptine on pre-synaptic dopaminergic receptors. This should mean that peripheric pre-synaptic dopaminergic receptors are involved in the physiopathology of Parkinson's disease.

Bromocriptine↗